Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook DOI Creative Commons
Junjie Zhou, Yuanming Feng, Ming Zhao

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13

Published: March 27, 2025

Head and neck cancer (HNC) critically affects patient survival quality of life, highlighting the need for optimized perioperative interventions. While conventional therapies face limitations in specificity toxicity, nanotechnology has emerged as a revolutionary approach. Preoperative application tumor-targeting nanoprobes enables molecular-level lesion identification via biomarker-specific conjugation spatially resolved fluorescence quantification. Intraoperatively, fluorescent nanomaterials enhance surgical precision through selective tumor accumulation, delineating malignant margins real time. Postoperatively, engineered nanocarriers improve therapeutic outcomes by delivering drugs with spatial control, minimizing off-target effects, enabling multimodal synergies. These nanotechnology-driven strategies collectively address critical challenges HNC management, including diagnostic sensitivity, intraoperative visualization, postoperative recurrence. Their inherent advantages—precision targeting, reduced systemic multifunctional integration—establish them cornerstone tools modern oncology. Future advancements nanomaterial design biocompatibility are poised to further refine efficacy, rates, patient-centered outcomes.

Language: Английский

Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook DOI Creative Commons
Junjie Zhou, Yuanming Feng, Ming Zhao

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13

Published: March 27, 2025

Head and neck cancer (HNC) critically affects patient survival quality of life, highlighting the need for optimized perioperative interventions. While conventional therapies face limitations in specificity toxicity, nanotechnology has emerged as a revolutionary approach. Preoperative application tumor-targeting nanoprobes enables molecular-level lesion identification via biomarker-specific conjugation spatially resolved fluorescence quantification. Intraoperatively, fluorescent nanomaterials enhance surgical precision through selective tumor accumulation, delineating malignant margins real time. Postoperatively, engineered nanocarriers improve therapeutic outcomes by delivering drugs with spatial control, minimizing off-target effects, enabling multimodal synergies. These nanotechnology-driven strategies collectively address critical challenges HNC management, including diagnostic sensitivity, intraoperative visualization, postoperative recurrence. Their inherent advantages—precision targeting, reduced systemic multifunctional integration—establish them cornerstone tools modern oncology. Future advancements nanomaterial design biocompatibility are poised to further refine efficacy, rates, patient-centered outcomes.

Language: Английский

Citations

0